| Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases K Papamichael, AS Cheifetz, GY Melmed, PM Irving, NV Casteele, ... Clinical Gastroenterology and Hepatology 17 (9), 1655-1668. e3, 2019 | 283 | 2019 |
| Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse K Papamichael, A Gils, P Rutgeerts, BG Levesque, S Vermeire, ... Inflammatory bowel diseases 21 (1), 182-197, 2015 | 249 | 2015 |
| Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab K Papamichael, KA Chachu, RK Vajravelu, BP Vaughn, J Ni, ... Clinical Gastroenterology and Hepatology 15 (10), 1580-1588. e3, 2017 | 224 | 2017 |
| European Crohn’s and Colitis Organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease G Doherty, KH Katsanos, J Burisch, M Allez, K Papamichael, A Stallmach, ... Journal of Crohn's and Colitis 12 (1), 17-31, 2018 | 195 | 2018 |
| Helicobacter pylori infection and endocrine disorders: is there a link? KX Papamichael, G Papaioannou, H Karga, A Roussos, GJ Mantzaris World journal of gastroenterology: WJG 15 (22), 2701, 2009 | 191 | 2009 |
| Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis K Papamichael, T Van Stappen, NV Casteele, A Gils, T Billiet, S Tops, ... Clinical Gastroenterology and Hepatology 14 (4), 543-549, 2016 | 176 | 2016 |
| Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study K Papamichael, E Archavlis, C Lariou, GJ Mantzaris Journal of Crohn's and Colitis 6 (9), 924-931, 2012 | 132 | 2012 |
| Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease K Papamichael, A Juncadella, D Wong, S Rakowsky, LA Sattler, ... Journal of Crohn's and Colitis 13 (8), 976-981, 2019 | 130 | 2019 |
| Helicobacter pylori infection and inflammatory bowel disease: is there a link? K Papamichael, P Konstantopoulos, GJ Mantzaris World journal of gastroenterology: WJG 20 (21), 6374, 2014 | 130 | 2014 |
| A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease AS Cheifetz, MT Abreu, W Afif, RK Cross, MC Dubinsky, EV Loftus Jr, ... Official journal of the American College of Gastroenterology| ACG 116 (10 …, 2021 | 123 | 2021 |
| Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease K Papamichael, RK Vajravelu, BP Vaughn, MT Osterman, AS Cheifetz Journal of Crohn's and Colitis 12 (7), 804-810, 2018 | 116 | 2018 |
| Infliximab in inflammatory bowel disease K Papamichael, S Lin, M Moore, G Papaioannou, L Sattler, AS Cheifetz Therapeutic advances in chronic disease 10, 2040622319838443, 2019 | 115 | 2019 |
| Use of anti-TNF drug levels to optimise patient management K Papamichael, AS Cheifetz Frontline gastroenterology 7 (4), 289-300, 2016 | 110 | 2016 |
| Etiology and management of lack or loss of response to anti–tumor necrosis factor therapy in patients with inflammatory bowel disease S Fine, K Papamichael, AS Cheifetz Gastroenterology & hepatology 15 (12), 656, 2019 | 108 | 2019 |
| Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases K Papamichael, EH Vogelzang, J Lambert, G Wolbink, AS Cheifetz Expert review of clinical immunology 15 (8), 837-848, 2019 | 98 | 2019 |
| Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies KH Katsanos, K Papamichael, JD Feuerstein, DK Christodoulou, ... Clinical Immunology 206, 9-14, 2019 | 96 | 2019 |
| Long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission K Papamichael, NV Casteele, A Gils, S Tops, S Hauenstein, S Singh, ... Clinical Gastroenterology and Hepatology 13 (6), 1103-1110, 2015 | 96 | 2015 |
| Therapeutic drug monitoring during induction of anti–tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window K Papamichael, NV Casteele, M Ferrante, A Gils, AS Cheifetz Inflammatory bowel diseases 23 (9), 1510-1515, 2017 | 90 | 2017 |
| How, when, and for whom should we perform therapeutic drug monitoring? S Vermeire, E Dreesen, K Papamichael, MC Dubinsky Clinical Gastroenterology and Hepatology 18 (6), 1291-1299, 2020 | 79 | 2020 |
| Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn’s disease K Papamichael, S Rakowsky, C Rivera, AS Cheifetz, MT Osterman Inflammatory bowel diseases 24 (10), 2266-2271, 2018 | 79 | 2018 |
Adam CheifetzBeth Israel Deaconess Medical CenterVerified email at bidmc.harvard.edu
